While medications for addiction treatment (MAT) and behavioral therapies are the primary treatment options for substance use disorders (SUDs), neuromodulation interventions have emerged as promising new treatments. These non-invasive therapies use electrical, magnetic, or ultrasound to alter the activity of neural circuits in the brain involved in reward and motivation and implicated in addiction (Oesterle et al., 2025). The goal is to directly influence brain function to red

In recent years, medications originally developed to treat Type 2 diabetes, obesity, and other weight-related conditions—such as semaglutide and liraglutide—are showing promise in treating substance use disorders (SUDs). These medications belong to a class of glucagon-like peptide-1 (GLP-1) receptor agonists and are marketed under brand names such as Ozempic®, Wegovy®, Victoza®, and Saxenda®.  GLP-1 is a naturally occurring hormone produced in the gut and brain that regulates

In recent years, medications originally developed to treat Type 2 diabetes, obesity, and other weight-related conditions—such as semaglutide and liraglutide—are showing promise in treating substance use disorders (SUDs). These medications belong to a class of glucagon-like peptide-1 (GLP-1) receptor agonists and are marketed under brand names such as Ozempic®, Wegovy®, Victoza®, and Saxenda®.  GLP-1 is a naturally occurring hormone produced in the gut and brain that regulates

According to the latest Monitoring the Future (MTF) Panel Study from the University of Michigan, young and midlife adults are reporting sharp increases in several emerging substance use behaviors, including nicotine pouches, cannabis, vaping, and psychedelics.  For 50 years, MTF surveys nationally representative samples of 8th, 10th, and 12th-graders, tracking trends in youth substance use and following a subset of 12th-grade participants into adulthood. Today, the MTF Panel

A new study published in BMJ Evidence-Based Medicine shows that any level of alcohol consumption can increase the risk of dementia. Researchers also found that tripling weekly alcohol consumption—whether from one to three drinks per week or three to nine—was associated with a 15% increased risk of developing dementia. In the study, researchers analyzed data from more than 550,000 adults between the ages of 56-72 years at baseline and genetic information from an additional 2

A new study published in the American Journal of Psychiatry finds that contingency management (CM)—a behavioral treatment that rewards individuals for meeting treatment milestones—can significantly reduce the risk of death among people with stimulant use disorder.

In a new study published in The New England Journal of Medicine , researchers with JCOIN’s Massachusetts Clinical Research Center found that providing medications for opioid use disorder (MOUD) during incarceration can improve outcomes and save lives after release. The study shows that individuals who received MOUD in jail were more likely to engage in treatment and less likely to experience an overdose within six months of release. The study evaluated the impact of a 2019 Ma

Study using AI to analyze community coalition meeting minutes from the HEALing Communities Study (HCS) identifies key themes and how they intersected with decisions when selecting evidence-based practices (EBPs) to reduce overdose deaths.

A study  published in JAMA Network Open  examined pharmacy barriers faced by patients prescribed buprenorphine to treat opioid use disorder (OUD) through telemedicine. The findings show that pharmacy-related challenges were common, with nearly one-third of study participants (31.9%) reporting going without buprenorphine at some point in the prior 12 months due to pharmacy-related barriers. Researchers surveyed 601 adults who were receiving treatment from a multistate telemedi